Z-0349-2023 Class III Terminated

Recalled by Primus Corporation Dba Trinity Biotech — Kansas City, MO

FDA device recall Z-0349-2023 was initiated by Primus Corporation Dba Trinity Biotech on Oct 5, 2021 and is designated Class III. Reason for recall: The Control Level I material value was showing results exceeding the upper limit of the acceptable range after a period of three (3) months. The unacceptable Control Level 1 value results in the… The recall status is terminated (terminated Aug 9, 2023). Affected quantity: 340 kits.

Recall details

Product Type
Devices
Report Date
Dec 7, 2022
Initiation Date
Oct 5, 2021
Termination Date
Aug 9, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
340 kits

Product description

A. MENARINI diagnostics Hb 9210 PREMIER, LEVEL1, LEVEL II, Hemoglobin A1c Controls for hemoglobin A1c Assay, REF 45052, part number 05-01-0926, A1c analysis

Reason for recall

The Control Level I material value was showing results exceeding the upper limit of the acceptable range after a period of three (3) months. The unacceptable Control Level 1 value results in the Analyzer generating an error code which stops further testing and nullifies associated patient samples, resulting in a delay in patient results and a potential delay in therapeutic modifications.

Distribution pattern

Turkey, India, Romania, Thailand, Vietnam, S. Korea, Peru, Pakistan Austria, UAE, Chile, Italy.

Code information

Lot 12161

Source

Dataset
openFDA device recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for Z-0349-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for Z-0349-2023. Report a data issue: hello@regdatalab.com.